Sign In
Buy RNA
$11.35
-0.110 (-0.96%)
At Close: Jul 31, 2026
Avidity Biosciences to Host Virtual Investor and Analyst Event on May 19, 2021
08:54am, Monday, 03'rd May 2021
LA JOLLA, Calif., May 3, 2021 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody Oligonucle
Avidity Biosciences to Participate in Upcoming Investor Conferences
04:05pm, Thursday, 25'th Mar 2021
LA JOLLA, Calif., March 25, 2021 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody Oligonuc
Edgewise Therapeutics Proposes Terms For $150 Million IPO
05:48pm, Tuesday, 23'rd Mar 2021
Edgewise Therapeutics has filed to raise $150 million in an IPO.
Avidity Biosciences Reports Fourth Quarter and Year-End 2020 Financial Results and Recent Highlights
04:05pm, Monday, 15'th Mar 2021
LA JOLLA, Calif., March 15, 2021 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody Oligonuc
Biotech Shares Have Soared Since 2020's Wave of IPOs
09:45am, Wednesday, 17'th Feb 2021
Indicative of investors' enthusiasm for new biotechs, the average gain in share price for the top 10 companies of the sector that went public in 2020 now tops 100%.
Avidity Biosciences Announces Addition to the Nasdaq Biotechnology Index
04:05pm, Monday, 21'st Dec 2020
LA JOLLA, Calif., Dec. 21, 2020 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody Oligonucl
U.S. IPO Week Ahead: DoorDash And Airbnb Kick Off The Unicorn Parade In A 6 IPO Week
02:26pm, Sunday, 06'th Dec 2020
The unicorn IPO parade is set to begin in the week ahead, with DoorDash and Airbnb leading the way. A total of six IPOs and two SPACs are scheduled to raise $7.2 billion.
